http://orcid.org/0000-0002-2533-4336
References
- Langley R, Blauvelt A, Armstrong A, et al. Guselkumab demonstrates superior long-term responses to secukinumab at week 48 in the treatment of moderate to severe psoriasis: results from the ECLIPSE trial. Poster presented at: 3rd Inflammatory Skin Disease Summit; 2018 December 12–15; Vienna, Austria.
- Langley R, Blauvelt A, Armstrong A, et al. Proportion of patients achieving a PASI 90 response (with 95% confidence interval) through week 48 by visit. Guselkumab comparison to secukinumab in the treatment of adults with moderate to severe plaque psoriasis. Janssen Biotech, Inc. [cited 2019 Jun 27].
- Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326–338.